Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013

    Volcano to Highlight its Physiology Expansion Efforts at EuroPCR 2013

  PR Newswire

  SAN DIEGO, May 21, 2013

SAN DIEGO, May 21, 2013 /PRNewswire/ --Volcano Corporation (NASDAQ: VOLC) a
leading developer and manufacturer of precision guided therapy tools designed
to enhance the diagnosis and treatment of coronary and peripheral vascular
disease, today announced it will highlight its efforts to expand research and
innovation surrounding its physiology technologies, including its Fractional
Flow Reserve (FFR) and iFR® (Instant Wave-Free Ratio™)[1] technologies, via
various clinical and educational presentations and events at EuroPCR 2013 in
Paris.

"Volcano is committed to making clinical and technological advances that
expand access to functional management," commented Michele Perrino, president
of Europe, Middle East, Africa, and India Operations of Volcano. "Our focus at
EuroPCR is to introduce our latest functional management technologies and
clinical data, and demonstrate their potential to improve both patient care
and the experience for our physician partners in Europe. Given our commitment
to provide physicians with choice, we are excited to feature iFR®, our novel
hyperemia-free software modality, and our Verrata™ Pressure Guide Wire, which
upon regulatory clearance will be our fifth new guide wire in five years."[2]

Volcano will formally launch its iFR® modality and CORE® Integrated System,
and display the Verrata™ Wire at the conference. Volcano will showcase its
future and currently available physiology, imaging, and multi-modality systems
products in the company's exhibit hall booth #M71.

Featured events for Volcano include four live case symposia demonstrating the
benefits of incorporating both FFR and our iFR® modality in simple and complex
cases, the presentation of the findings from the Adenosine Vasodilator
Independent Stenosis Evaluation II (ADVISE II) study data at a hot line
session, and over 10 scientific podium presentations featuring advanced
physiology using Volcano products.

Key Events Wednesday, May 22, 10:50 – 11:30 a.m. Complex bifurcation stenting:
LIVE demonstration of emerging techniques LIVE iFR® demonstration from Erasmus
University Medical Center, Thorax Center – Rotterdam, The NetherlandsTheatre
Bleu

Thursday, May 23, 9:45 - 11:45 a.m. Adenosine Vasodilator Independent Stenosis
Evaluation II (ADVISE II) Hot Line - Evolving procedural strategiesRoom
351

Thursday, May 23, 4:45 – 6:45 p.m. Physiological Stenosis Assessment with FFR
and Instant Wave-Free Ratio: We Need Both! Live case demonstrations (simple
and multivessel disease) from St. Thomas' Hospital, London, followed by panel
discussionsTheatre Bordeaux

Friday, May 24, 9:00 – 12:30 p.m. Complex cardiovascular interventions and new
techniques – Master LIVE demonstrations Continuous LIVE FFR and iFR®
demonstrations from Sunninghill and Sunward Park Hospitals, South Africa and
St Thomas' Hospital – London, United KingdomMain Arena

Daily, 12:00 – 3:00 p.m. Meet the iFR® Experts Booth #M71

About Volcano Corporation Volcano Corporation is revolutionizing the medical
device industry with a broad suite of technologies that make imaging and
therapy simpler, more informative and less invasive. Its products empower
physicians around the world with a new generation of analytical tools that
deliver more meaningful information - using sound and light as the guiding
elements. Founded in cardiovascular care and expanding into other specialties,
Volcano is changing the assumption about what is possible in improving patient
outcomes by combining imaging and therapy together.

Forward-Looking Statements This press release contains forward-looking
statements within the meaning of the U.S. Private Securities Litigation Reform
Act of 1995. Any statements in this release that are not historical facts may
be considered "forward-looking statements". Forward-looking statements are
based on management's current expectations and are subject to risks and
uncertainties which may cause Volcano's results to differ materially and
adversely from the statements contained herein. Some of the potential risks
and uncertainties that could cause actual results to differ include the pace
and extent of market adoption of the company's products and technologies;
unexpected clinical trial results, including unexpected new clinical data and
unexpected additional analysis of existing clinical data; unexpected
regulatory actions or delays or government regulation generally; the company's
ability to obtain or maintain patent or other proprietary intellectual
property protection; competition in general; government, industry and general
public pricing pressures; unexpected manufacturing issues; growth strategies;
timing and achievement of product development milestones; outcome of ongoing
litigation; the impact and benefits of market development; product
introductions; unexpected new data, safety and technical issues; market
conditions; and other risks inherent to medical device development and
commercialization. These and additional risks and uncertainties are more fully
described in Volcano's filings made with the Securities and Exchange
Commission, including ourrecent quarterly report on Form 10-Q. Undue reliance
should not be placed on forward-looking statements which speak only as of the
date they are made. Volcano undertakes no obligation to update any
forward-looking statements to reflect new information, events or circumstances
after the date they are made, or to reflect the occurrence of unanticipated
events.

[1]Our iFR® software modality is approved in CE mark countries.[2]Verrata™
Pressure Guide Wire is 510(k) and CE mark pending, and is not currently
commercially available for sale.

Website: http://www.volcanocorp.com
Contact: Edrienne Brandon, ebrandon@volcanocorp.com, +1-858-720-4136 or
Investor contact, Neal Rosen, nrosen@volcanocorp.com, +1-650-458-3014